Timpani Capital Management LLC bought a new stake in shares of Amedisys Inc (NASDAQ:AMED) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 78,401 shares of the health services provider’s stock, valued at approximately $4,924,000. Amedisys makes up 1.8% of Timpani Capital Management LLC’s holdings, making the stock its 8th biggest position. Timpani Capital Management LLC owned 0.23% of Amedisys at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in AMED. Bank of Montreal Can boosted its stake in Amedisys by 8,881.4% during the first quarter. Bank of Montreal Can now owns 34,848 shares of the health services provider’s stock valued at $1,780,000 after buying an additional 34,460 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Amedisys by 1.8% during the first quarter. Louisiana State Employees Retirement System now owns 11,400 shares of the health services provider’s stock valued at $582,000 after buying an additional 200 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Amedisys by 2.3% during the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock valued at $157,000 after buying an additional 70 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Amedisys by 77.7% during the first quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock valued at $1,854,000 after buying an additional 15,875 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its stake in Amedisys by 8.0% during the first quarter. Great West Life Assurance Co. Can now owns 40,062 shares of the health services provider’s stock valued at $2,045,000 after buying an additional 2,960 shares in the last quarter. 96.80% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently weighed in on AMED. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research note on Wednesday, July 26th. Bank of America Corporation assumed coverage on Amedisys in a research report on Monday, August 21st. They issued a “neutral” rating and a $55.00 price target for the company. BidaskClub upgraded Amedisys from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Finally, Royal Bank Of Canada reiterated a “hold” rating and issued a $56.00 price target on shares of Amedisys in a research report on Monday, June 5th. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $56.33.

In related news, Director Bruce D. Perkins acquired 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the acquisition, the director now owns 15,825 shares of the company’s stock, valued at approximately $737,445. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the completion of the sale, the insider now owns 10,488 shares of the company’s stock, valued at approximately $524,400. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/09/timpani-capital-management-llc-buys-shares-of-78401-amedisys-inc-amed.html.

Amedisys Inc (NASDAQ AMED) traded down 0.38% during trading on Friday, hitting $51.85. The company had a trading volume of 205,727 shares. The firm has a 50-day moving average of $50.35 and a 200 day moving average of $54.72. Amedisys Inc has a 12-month low of $34.58 and a 12-month high of $65.91. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 44.32 and a beta of 0.84.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. The business had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.42 earnings per share. On average, equities research analysts forecast that Amedisys Inc will post $2.21 earnings per share for the current year.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.